Ramp Chases $40B While TTEC Cuts 401(k)s and the Week Funding Felt Uneven

Ramp is six months into a $32B valuation and already in talks for $40B

Ramp is reportedly negotiating another $750 million at a $40 billion-plus valuation, barely half a year after closing a round at $32B. That's a 25% bump in six months for a spend-management platform that still competes with corporate Amex cards and Brex.

The brief doesn't spell out what changed between November and now — no new product line, no acquisition mentioned — so either the numbers got a lot better or the market decided fintech infra is back. Either way, raising at this cadence signals Ramp expects to stay private longer than most unicorns from the 2021 cohort, which is interesting given how many of those peers are still underwater or stuck in secondary-market limbo.

If the round closes at $40B, Ramp will be one of the most valuable private companies in the U.S. that doesn't make frontier AI models. That's a narrow club.

TTEC pauses 401(k) contributions for staff while peers trim benefits

On the other end of the spectrum, TTEC — a $2 billion tech consulting firm — just paused 401(k) employer contributions for staff. The article doesn't give a timeline for reinstatement or cite a specific revenue miss, but the move lands in a cluster of similar cost cuts at consulting shops (Deloitte and Zoom are name-checked as peers trimming benefits).

Pausing retirement contributions is a lever companies pull when they want to preserve headcount but need to shave payroll expense fast. It's also the kind of cut that doesn't show up in a layoff headline but hits morale harder than a one-time bonus skip.

The juxtaposition with Ramp's funding blitz is stark: one company is adding billions in paper value while another is clawing back a few basis points of comp. Both are responses to the same macro environment — just from very different starting positions.

Develo raises $14M for a pediatrics-focused EMR

Develo closed a $14 million Series A led by Blueprint Equity to build an electronic medical records system specifically for pediatrics. CEO Aaron Sin told Axios Pro the vertical focus matters because pediatric workflows — vaccination schedules, growth charts, parent communication — don't map cleanly onto adult-oriented EMRs.

This is one of those "obvious in hindsight" pivots: general-purpose EMRs dominate the market (Epic, Cerner, Athenahealth), but they're notoriously bad at edge cases, and kids are an edge case in almost every clinical dimension. If Develo can own the pediatrician segment the way Tebra grabbed small private practices, $14M won't be the last check.

Propel Bio Partners doubles down on founder-led biotech

Propel Bio Partners announced an expansion of its investment strategy targeting early-stage founder-led companies in diagnostics, therapeutics, precision medicine, and digital health. The release namechecks Leen Kawas, Propel's managing partner, and frames the firm's thesis around "a new generation of biotech founders."

This is marketing language, but it's also a real shift: a decade ago, most biotech VCs wanted academic PIs or pharma execs at the helm. Now funds are betting on technical founders who can code and fundraise in parallel, which aligns with the rising prominence of computational biology and AI-driven drug discovery. Propel didn't disclose fund size or portfolio names, so this is more "we exist and we have a pitch" than breaking news.

A scooter founder's AI startup raises $16M from a16z

Buried in the TechCrunch AI roundup is Pit, a new AI startup from the co-founders of Voi (the European scooter company). Pit just raised a $16 million seed led by Andreessen Horowitz.

The brief doesn't say what Pit actually does — "AI startup" is doing a lot of work in that sentence — but a16z writing a $16M seed check to mobility operators pivoting into AI is a decent signal that the "founder pedigree" box still matters more than the deck in certain rounds. Voi scaled to hundreds of cities and burned through a few hundred million dollars before the scooter market imploded, so the team knows how to run ops at scale. Whether that translates to AI infra is the $16M question.

The week's pattern: funding is back, but only for some

If you zoom out, the through line is bifurcation. Ramp can raise at a $40B valuation while TTEC cuts retirement benefits. Pediatric EMR startups and biotech funds are announcing rounds while a $2B consulting firm is trimming comp. The venture market isn't frozen — it's just picking winners with a narrower filter than it did three years ago.

The other pattern: a lot of these stories are either very early (seed, Series A) or very late (Ramp's pre-IPO mega-rounds). The messy middle — Series B and C companies that raised in 2021 and haven't hit breakout growth — is still mostly absent from the headlines. That's the cohort to watch if you want to know whether 2026 is actually a recovery or just a tale of two markets.